TIME TO
CHALLENGE

EXPECTATIONS IN METASTATIC CASTRATION-RESISTANT
PROSTATE CANCER TREATMENT

This website is intended for UK healthcare professionals only.
 Adverse event reporting information can be found at the bottom of the page.

LYNPARZA (olaparib) monotherapy and in combination with abiraterone and prednisone or prednisolone are the first PARP inhibitor therapy options for metastatic castration-resistant prostate cancer (mCRPC) recommended by NICE and accepted by the SMC1-4

 

LYNPARZA combination therapy for mCRPC

NICE recommended and SMC accepted for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated1,2

LYNPARZA tablets are indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated.5

Two older men standing side by side both looking at the camera
Two older men standing side by side both looking at the camera

 

 

Portrait of an older man looking serious
Portrait of an older man looking serious

 

LYNPARZA monotherapy for BRCAm mCRPC

NICE recommended and SMC accepted for treating hormone-relapsed mCRPC with BRCA1/2-mutations that has progressed after NHA (such as abiraterone or enzalutamide) in adults3,4

LYNPARZA tablets are indicated as monotherapy for the treatment of adult patients with mCRPC and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy, including an NHA.5

Discover useful information for managing LYNPARZA treatment in your patients

There is a range of resources readily available to support you in prescribing LYNPARZA to
patients with mCRPC

Still from an animation that explains the Lynparza combination therapy mode of action
Still from an animation that explains the Lynparza combination therapy mode of action

Find out about LYNPARZA and abiraterone's hypothesised mode of action

 

Watch the MoA video

Illustration of two medicine bottles
Illustration of two medicine bottles

Find out how to administer LYNPARZA


 

View the dosing schedule

Please refer to the SmPC for further information to minimise the risks associated with the use of the medicine before making any prescribing decisions.

References

  1. Olaparib with abiraterone for untreated hormone relapsed metastatic prostate cancer. NICE TA951. February 2024. Available at https://www.nice.org.uk/guidance/ta951/resources/olaparib-with-abiraterone-for-untreated-hormonerelapsed-metastatic-prostate-cancer-pdf-82615723963333. Accessed June 2024.
  2. Scottish Medicines Consortium. Olaparib (Lynparza). March 2024. Available at: https://www.scottishmedicines.org.uk/medicines-advice/olaparib-lynparza-mcrpc-full-smc2617/. Accessed June 2024.
  3. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer. May 2023. https://www.nice.org.uk/guidance/ta887/resources/olaparib-for-previously-treated-brca-mutationpositive-hormonerelapsed-metastatic-prostate-cancer-pdf-82613738657221. Accessed June 2024.
  4. Scottish Medicines Consortium, SMC2366. Olaparib (Lynparza). October 2021. https://www.scottishmedicines.org.uk/media/6338/olaparib-lynparza-final-september-2021-for-website.pdf. Accessed June 2024.
  5. LYNPARZA (olaparib). Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/9488/ smpc#about-medicine. Accessed June 2024.

 

Abbreviations

BRCA1/2m=BRCA1/2 mutation; mCRPC=metastatic castration-resistant prostate cancer; MoA=mode of action; NHA=new hormonal agent; NICE=National Institute for Health and Care Excellence; PARP=poly (ADP-ribose) polymerase; SMC=Scottish Medicines Consortium.

February 2025 | Job code: GB-64095